R&G PharmaStudies Co., Ltd.

SZSE:301333 Stock Report

Market Cap: CN¥3.7b

R&G PharmaStudies Balance Sheet Health

Financial Health criteria checks 5/6

R&G PharmaStudies has a total shareholder equity of CN¥1.8B and total debt of CN¥33.1M, which brings its debt-to-equity ratio to 1.8%. Its total assets and total liabilities are CN¥2.2B and CN¥435.7M respectively. R&G PharmaStudies's EBIT is CN¥113.9M making its interest coverage ratio -5.1. It has cash and short-term investments of CN¥1.7B.

Key information

1.8%

Debt to equity ratio

CN¥33.14m

Debt

Interest coverage ratio-5.1x
CashCN¥1.70b
EquityCN¥1.81b
Total liabilitiesCN¥435.70m
Total assetsCN¥2.24b

Recent financial health updates

No updates

Recent updates

R&G PharmaStudies' (SZSE:301333) Dividend Will Be Reduced To CN¥0.20

Jul 01
R&G PharmaStudies' (SZSE:301333) Dividend Will Be Reduced To CN¥0.20

Is There An Opportunity With R&G PharmaStudies Co., Ltd.'s (SZSE:301333) 27% Undervaluation?

Jun 06
Is There An Opportunity With R&G PharmaStudies Co., Ltd.'s (SZSE:301333) 27% Undervaluation?

Shareholders Will Be Pleased With The Quality of R&G PharmaStudies' (SZSE:301333) Earnings

Apr 29
Shareholders Will Be Pleased With The Quality of R&G PharmaStudies' (SZSE:301333) Earnings

Financial Position Analysis

Short Term Liabilities: 301333's short term assets (CN¥2.0B) exceed its short term liabilities (CN¥374.4M).

Long Term Liabilities: 301333's short term assets (CN¥2.0B) exceed its long term liabilities (CN¥61.3M).


Debt to Equity History and Analysis

Debt Level: 301333 has more cash than its total debt.

Reducing Debt: 301333's debt to equity ratio has increased from 0% to 1.8% over the past 5 years.

Debt Coverage: 301333's debt is well covered by operating cash flow (637.3%).

Interest Coverage: 301333 earns more interest than it pays, so coverage of interest payments is not a concern.


Balance Sheet


Discover healthy companies